Cutaneous T-cell lymphomas: A review of new discoveries and treatments

Current Treatment Options in Oncology

Volumn 13, Issue 1, 2012, Pages 102-121

  Bloom, Tara ^a   Kuzel, Timothy M ^b   Querfeld, Christiane ^c   Guitart, Joan ^b   Rosen, Steven T ^d  

^a RUSH MEDICAL COLLEGE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cutaneous CD30+ T cell lymphoproliferative disorders; Cutaneous T Cell lymphomas (CTLC); Denileukin diftitox; Retinoids; Treatment

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BEXAROTENE; BORTEZOMIB; CARMUSTINE; CHLORMETHINE; CLOBETASOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DOXORUBICIN; ENZASTAURIN; ETRETIN; FAS ANTIGEN; FLUDARABINE; GEMCITABINE; LENALIDOMIDE; METHOTREXATE; NOTCH RECEPTOR; PLACEBO; PRALATREXATE; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; PSORALEN; ROMIDEPSIN; TAZAROTENE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ADRENAL INSUFFICIENCY; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ASTHENIA; AUTOIMMUNE DISEASE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER STAGING; CENTRAL HYPOTHYROIDISM; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; CUTANEOUS T CELL LYMPHOMA; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; IMMUNE DEFICIENCY; INFECTION; LEG EDEMA; LEUKEMIA; MALAISE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYCOSIS; MYCOSIS FUNGOIDES; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PRACTICE GUIDELINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PRURITUS; PUVA; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SEZARY SYNDROME; SKIN BURNING SENSATION; STOMATITIS; T CELL LEUKEMIA; TOTAL SKIN ELECTRON THERAPY; TUMOR GROWTH; TUMOR VOLUME; VASCULAR DISEASE; VASCULAR LEAK SYNDROME;

ALGORITHMS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; FEMALE; HUMANS; LYMPH NODES; LYMPHOMA, T-CELL, CUTANEOUS; MALE; PALLIATIVE CARE; PRACTICE GUIDELINES AS TOPIC; PUVA THERAPY; SKIN; SKIN NEOPLASMS; TUMOR BURDEN; UNITED STATES;

EID: 84857659431     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-011-0179-8     Document Type: Review

References (133)

1. P Bradford S Devesa W Anderson, et al. 2009 Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases Blood 113 21 5064 5073 19279331 1:CAS:528:DC%2BD1MXmsl2nsrs%3D
2. MA Weinstock B Gardstein 1999 Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality Am J Public Health 89 1240 1244 10432915 1:STN:280:DyaK1MzmtFGrsw%3D%3D (Pubitemid 29359582)
3. SO Arulogun HM Prince J Ng, et al. 2008 Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation Blood 112 3082 3087 18647960 1:CAS:528:DC%2BD1cXht1Omur7M
4. R Willemze ES Jaffe G Burg, et al. 2005 WHO-EORTC classification for cutaneous lymphomas Blood 105 10 3768 3785 15692063 1:CAS:528: DC%2BD2MXktlSrs74%3D (Pubitemid 40656118)
5. D Jones NH Dang M Duvic LT Washington YO Huh 2001 Absence of CD26 expression is a useful marker fordiagnosis of T-cell lymphoma in peripheral blood Am J Clin Pathol 115 6 885 892 11392886 1:CAS:528:DC%2BD3MXksVyhtr0%3D (Pubitemid 32476716)
6. Y Iwai S Terawaki T Honjo 2005 PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cellsby enhanced recruitment of effector T cells Int Immunol 17 2 133 144 15611321 1:CAS:528:DC%2BD2MXmsVyjtg%3D%3D (Pubitemid 40246578)
7. S Samimi B Benoit K Evans, et al. 2010 Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression Arch Dermatol 146 12 1382 1388 20713771 1:CAS:528: DC%2BC3MXjt1Sgtg%3D%3D
8. Y Iwai S Terawaki T Honjo 2005 PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumorcells by enhanced recruitment of effector T cells Int Immunol 17 2 133 144 15611321 1:CAS:528:DC%2BD2MXmsVyjtg%3D%3D (Pubitemid 40246578)
9. JC Pui D Allman L Xu, et al. 1999 Notch1 expression in early lymphopoiesis influences B versus T lineage determination Immunity 11 3 299 308 10514008 1:CAS:528:DyaK1MXmsFWmsbg%3D (Pubitemid 29463238)
10. MR Kamstrup LM Gjerdrum E Biskup, et al. 2010 Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma Blood 116 14 2504 2512 20538790 1:CAS:528:DC%2BC3cXhtlyqt7bO
11. C Hu A Dievart M Lupien, et al. 2006 Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland developmentand induces mammary tumors Am J Pathol 168 3 973 990 16507912 1:CAS:528: DC%2BD28XislGgurs%3D (Pubitemid 43327749)
12. CC Pinnix JT Lee ZJ Liu, et al. 2009 Active Notch1 confers a transformed phenotype to primary human melanocytes Cancer Res 69 13 5312 5320 19549918 1:CAS:528:DC%2BD1MXnvFWqu78%3D
13. E Rosati R Sabatini G Rampino, et al. 2009 Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells Blood 113 4 856 865 18796623 1:CAS:528:DC%2BD1MXhtlGhtLs%3D
14. MB Wozniak L Tracey PL Ortiz-Romero 2009 Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways Br J Dermatol 160 1 92 102 18945306 1:CAS:528:DC%2BD1MXhvVCitbs%3D
15. ZW Li WS Dalton 2006 Tumor microenvironment and drug resistance in hematologic malignancies Blood Rev 20 333 342 16920238 (Pubitemid 44691998)
16. C Brender M Nielsen K Kaltoft, et al. 2001 STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma Blood 97 1056 1062 11159537 1:CAS:528:DC%2BD3MXht1Gisr0%3D (Pubitemid 32154293)
17. J Wu M Nihal J Siddiqui EC Vonderheid GS Wood 2009 Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation J Invest Dermatol 129 5 1165 1173 18923451 1:CAS:528:DC%2BD1MXksFarsr0%3D
18. CL Jones EM Wain CC Chu, et al. 2010 Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation J Invest Dermatol 130 4 1116 1125 19759548 1:CAS:528: DC%2BC3cXjt1Kqu7c%3D
19. J Wu GS Wood 2011 Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancementof sensitivity to apoptosis in cutaneous T-cell lymphoma Arch Dermatol 147 4 443 449 21173302 1:CAS:528:DC%2BC3MXmsVCru7o%3D
20. M Rovedo N Krett S Rosen 2011 Inhibition of Glycogen Synthase Kinase-3 Increases the Cytotoxicity of Enzastaurin J Invest Dermatol 131 1442 1449 21471986 1:CAS:528:DC%2BC3MXnsFWgs74%3D This article highlighted novel studies regarding the potential for using Enzastaurin as a viable treatment option for CTCL.
21. C Querfeld MA Rizvi TM Kuzel, et al. 2006 The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway J Invest Dermatol 126 1641 1647 16645590 1:CAS:528:DC%2BD28Xls1Kgsro%3D
22. F Trautinger R Knobler R Willemze, et al. 2006 EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome Eur J Cancer 42 1014 1030 16574401
23. R van Doorn MS van Kester R Dijkman, et al. 2009 Oncogenomic analysis of mycosis fungoides reveals major differences with Sézary syndrome Blood 113 1 127 136 18832135 This article brought to light a very interesting observation and provided sound rationale for looking at the two diseases as separate entities.
24. N Booken A Gratchev J Utikal, et al. 2008 Sézary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3 Leukemia 22 393 399 18033314 1:CAS:528:DC%2BD1cXhvVyltLk%3D (Pubitemid 351250545)
25. MH Vermeer R Van Doorn R Dijkman, et al. 2008 Novel and highly recurrent chromosomal alterations in Sézary syndrome Cancer Res 68 2689 2698 18413736 1:CAS:528:DC%2BD1cXks1Gitb8%3D (Pubitemid 351556266)
26. JJ Campbell RA Clark R Watanabe, et al. 2010 Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors Blood 116 5 767 771 20484084 1:CAS:528: DC%2BC3cXhtVCku7zE This article brought to light a very interesting observation and provided sound rationale for looking at the two diseases as separate entities.
27. E Laharanne N Oumouhou F Bonnet, et al. 2010 Genome-Wide Analysis of Cutaneous T-Cell Lymphomas Identifies Three Clinically Relevant Classes J Invest Dermatol 130 6 1707 1718 20130593 1:CAS:528:DC%2BC3cXlvFOjt7o%3D This article looks at three different cases and demonstrates novel information on genomics in CTCL.
28. E Laharanne E Chevret Y Idrissi, et al. 2010 CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma Mod Pathol 23 4 547 558 20118908 1:CAS:528:DC%2BC3cXktVCqsbk%3D
29. IC Navas PL Ortiz-Romero R Villuendas, et al. 2000 p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides Am J Pathol 156 1565 1572 10793068 1:CAS:528:DC%2BD3cXjslKltbc%3D (Pubitemid 30646696)
30. A Carbone L Bernardini F Valenzano, et al. 2008 Array-based comparative genomic hybridization in early-stage mycosis fungoides: recurrent deletion of tumor suppressor genes BCL7A, SMAC/DIABLO, and RHOF Genes Chromosomes Cancer 47 1067 1075 18663754 1:CAS:528:DC%2BD1cXhtlWns7jN
31. GA Calin CD Dumitru M Shimizu, et al. 2002 Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proc Natl Acad Sci U S A 99 15524 15529 12434020 1:CAS:528:DC%2BD3sXjvVOl (Pubitemid 35403967)
32. H Nevala L Karenko L Vakeva A Ranki 2001 Proapoptotic and antiapoptotic markers in cutaneous T-cell lymphoma skin infiltrates and lymphomatoid papulosis Br J Dermatol 145 928 937 11899146 1:STN:280:DC%2BD387ms1aitQ%3D%3D (Pubitemid 34204467)
33. CD Klemke D Brenner EM Weiss, et al. 2009 Lack of T-Cell receptor-induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-Cell lymphoma cells from activation-induced cell death Cancer Res 69 10 4175 4183 19435902 1:CAS:528:DC%2BD1MXlvFWlt70%3D
34. IV Litvinov DA Jones D Sasseville, et al. 2010 Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma Clin Cancer Res 16 7 2106 2114 20233883 1:CAS:528:DC%2BC3cXktFynsrc%3D
35. F Lansigan F Foss 2010 Current and emerging treatment strategies for cutaneous T-cell lymphoma Drugs 70 3 273 286 20166766 1:CAS:528: DC%2BC3cXkvFOnu7s%3D
36. C Querfeld S Rosen T Kuzel, et al. 2005 Long-term follow-up of patients with early-stage cutaneous T-Cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy Arch Dermatol 141 305 311 15781671 (Pubitemid 40365446)
37. JJ Herrmann HH Roenigk Jr H Hönigsmann 1995 Ultraviolet radiation for treatment of cutaneous T-cell lymphoma Hematol Oncol Clin North Am 9 1077 1088 8522485 1:STN:280:DyaK28%2FoslGltQ%3D%3D
38. Hönigsmann H, Tanew A. Photo(chemo)therapy for cutaneous T-cell lymphoma. In: Krutmann J, Hönigsmann H, Elmets CA, editors. Dermatologic phototherapy and photodiagnostic methods. 2nd ed. Heidelberg: Springer; 2009. p. 135-49.
39. F Trautinger R Knobler R Willemze, et al. 2006 EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome Eur J Cancer 42 1014 1030 16574401
40. F Trautinger 2011 Phototherapy of mycosis fungoides Photodermatol Photoimmunol Photomed 27 2 68 74 21392108
41. Rosen ST, Querfeld C, Kuzel TM, Guitart J. Cutaneous T-Cell lymphomas: a guide for the community oncologist, 2nd edn. 2008.
42. HS Zackheim M Kashani-Sabet S Amin 1998 Topical corticosteroids for mycosis fungoides: experience in 79 patients Arch Dermatol 134 8 949 954 9722724 1:CAS:528:DyaK1cXlslGqtrs%3D (Pubitemid 28385316)
43. YH Kim G Martinez A Varghese, et al. 2003 Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience Arch Dermatol 139 2 165 173 12588222 1:CAS:528:DC%2BD3sXhslehtLk%3D (Pubitemid 36216254)
44. HS Zackheim T Cutaneous 1999 cell lymphoma: update of treatment Dermatology 199 102 105 10559573 1:STN:280:DC%2BD3c%2FisFKisA%3D%3D
45. RA Abbott SJ Whittaker SL Morris, et al. 2009 Bexarotene therapy for mycosis fungoides and Sézary syndrome Br J Dermatol 160 6 1299 1307 19222457 1:CAS:528:DC%2BD1MXotlSitrY%3D
46. P Heald M Mehlmauer AG Martin, et al. 2003 Topical bexarotene treatment for patients with refractory or persistent early stage cutaneous T-cell lymphoma: results of the phase III clinical trial J Am Acad Dermatol 49 801 815 14576658 (Pubitemid 37314867)
47. D Breneman M Duvic T Kuzel, et al. 2002 Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma Arch Dermatol 138 3 325 332 11902983 1:CAS:528:DC%2BD38XislOrtrg%3D (Pubitemid 34226330)
48. N Apisarnthanarax R Talpur S Ward, et al. 2004 Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study J Am Acad Dermatol 50 4 600 607 15034511 (Pubitemid 38393171)
49. D Navi N Riaz YS Levin NC Sullivan, et al. 2011 The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides Arch Dermatol 147 5 561 567 21576575
50. CE Introcaso B Micaily SK Richardson, et al. 2008 Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome J Am Acad Dermatol 58 4 592 595 18249469
51. M Duvic K Hymes P Heald, et al. 2001 Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results J Clin Oncol 19 9 2456 2471 11331325 1:CAS:528:DC%2BD3MXjvVeluro%3D (Pubitemid 32391217)
52. C Assaf M Bagot R Dummer 2006 Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion Br J Dermatol 155 261 266 16882161 1:CAS:528:DC%2BD28XpsVers78%3D (Pubitemid 44050557)
53. G Gorgun F Foss 2002 Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox Blood 100 4 1399 1403 12149223 1:CAS:528: DC%2BD38Xmt12iur8%3D (Pubitemid 34864297)
54. F Foss MF Demierre G DiVenuti 2005 A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma Blood 106 2 454 457 15811959 1:CAS:528:DC%2BD2MXmtleqsLk%3D (Pubitemid 40981237)
55. K Nakase K Kita K Nasu, et al. 1994 Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms Am J Hematol 46 179 183 7514848 1:STN:280:DyaK2c3kvFKktw%3D%3D (Pubitemid 24206741)
56. J Nichols F Foss TM Kuzel, et al. 1997 Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies Eur J Cancer 33 suppl 1 S34 S36 9166099 1:CAS:528:DyaK2sXjtFegu7g%3D
57. Prince HM, Duvic M, Martin A et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-celllymphoma. J Clin Oncol. 2010;28(11):1870-7. Epub 2010 Mar 8.
58. F Foss M Duvic EA Olsen 2011 Predictors of complete responses with denileukin diftitox in cutaneous T-cell lymphoma Am J Hematol 86 7 627 630 10.1002/ajh.22039 21674574
59. E Olsen M Duvic A Frankel, et al. 2001 Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma J Clin Oncol 19 376 388 11208829 1:CAS:528:DC%2BD3MXhtVekt70%3D (Pubitemid 32112849)
60. JA Zic 2003 The treatment of cutaneous T-cell lymphoma with photopheresis Dermatol Ther 16 337 346 14686977 (Pubitemid 38044678)
61. M Duvic N Chiao R Talpur 2003 Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma J Cutan Med Surg 7 3 7 12958700
62. R Knobler C Jantschitsch 2003 Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma Transfus Apher Sci 28 81 89 12620272 1:STN:280:DC%2BD3s7gvVyrug%3D%3D (Pubitemid 36298594)
63. EA Olsen AH Rook J Zic, et al. 2011 Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) J Am Acad Dermatol 64 2 352 404 21145619 This review was thorough and explained and pathogenesis and all treatments of Sezary syndrome.
64. E Bisaccia EC Vonderheid L Geskin 2009 Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma Br J Dermatol 161 1 167 169 19298276 1:STN:280:DC%2BD1Mvnt1ajsw%3D%3D
65. LD Wilson GW Jones D Kim, et al. 2000 Experience with total skin electron beam therapy in combination with extracorporeal photophoresis in the management of patients with erythrodermic (T4) mycosis fungoides J Am Acad Dermatol 43 54 60 10863224 1:STN:280:DC%2BD3czitlehtA%3D%3D (Pubitemid 30439713)
66. KR Suchin AJ Cucchiara SL Gottleib, et al. 2002 Treatment of cutaneous T-cell lymphoma with combined immunotherapy: a 14-year experience at a single institution Arch Dermatol 138 1054 1060 12164743 (Pubitemid 34875609)
67. JE Bolden MJ Peart RW Johnstone 2006 Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 9 769 784 16955068 1:CAS:528:DC%2BD28XptVCltrY%3D (Pubitemid 44348499)
68. MJ Peart GK Smyth RK Laar, et al. 2005 Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors Proc Natl Acad Sci U S A 102 3697 3702 10.1073/pnas.0500369102 15738394 1:CAS:528:DC%2BD2MXisVOgsb0%3D (Pubitemid 40354674)
69. RL Piekarz R Robey V Sandor, et al. 2001 Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report Blood 98 9 2865 2868 11675364 1:CAS:528:DC%2BD3MXotVegt74%3D
70. SJ Whittaker MF Demierre EJ Kim, et al. 2010 Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma J Clin Oncol 28 4485 20697094 1:CAS:528:DC%2BC3cXhsVejt7zL This article explained the results of the most recent multicenter, international study of romidepsin in CTCL patients.
71. RL Piekarz R Frye M Turner, et al. 2009 Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma J Clin Oncol 27 5410 5417 19826128 1:CAS:528:DC%2BD1MXhsFKkt7vO
72. RL Piekarz DL Sackett SE Bates 2007 Histone deacetylase inhibitors and demethylating agents: Clinical development of histone deacetylase inhibitors for cancer therapy Cancer J 13 30 39 17464244 1:CAS:528:DC%2BD2sXlsVWhtbc%3D
73. M Duvic R Talpur X Ni C Zhang P Hazarika C Kelly, et al. 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 1 31 39 16960145 1:CAS:528: DC%2BD2sXivVyrt7g%3D (Pubitemid 46053039)
74. C Zhang V Richon X Ni, et al. 2005 Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T cell lymphoma cells: relevance to mechanism of therapeutic action J Invest Dermatol 125 1045 1052 16297208 1:CAS:528:DC%2BD2MXht1GrtrvN
75. M Duvic R Talpur X Ni, et al. 2007 Phase 2 trial of oral vorinostat for refractory cutaneous T cell lymphoma Blood 109 31 39 16960145 1:CAS:528:DC%2BD2sXivVyrt7g%3D
76. MB Wozniak R Villuendas JR Bischoff, et al. 2010 Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma Haematologica 95 4 613 621 20133897 1:CAS:528:DC%2BC3cXhtlWjsL7E
77. GR Stark IM Kerr BR Williams, et al. 1998 How cells respond to interferons Annu Rev Biochem 67 227 264 9759489 1:CAS:528:DyaK1cXlsFOmsLo%3D (Pubitemid 28411130)
78. A Avilés MJ Nambo N Neri, et al. 2007 Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome Cancer Biother Radiopharm 22 6 836 840 18158775
79. V Chiarion-Sileni A Bononi CV Fornasa, et al. 2002 Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma Cancer 95 569 575 12209749 1:CAS:528: DC%2BD38XmsVWrurc%3D (Pubitemid 34810182)
80. S Rupoli G Goteri S Pulini, et al. 2005 Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides Eur J Haematol 75 136 145 16000130 1:CAS:528:DC%2BD2MXoslCqtLY%3D (Pubitemid 41008284)
81. Stadler RKA, Luger T, Sterry W. Prospective, randomized, multicentre clinical trial on the use of interferon a-2a plus PUVA versus PUVA monotherapy in patients with cutaneous T-cell lymphoma, stages I and II. J Clin Oncology, ASCO Annual Meeting Proceedings Part I 2006;24 (Suppl.):18s. (abstr 7541).
82. EA Olsen ST Rosen RT Vollmer, et al. 1989 Interferon alfa-2a in the treatment of cutaneous T cell lymphoma J Am Acad Dermatol 20 3 395 407 2783939 1:STN:280:DyaL1M7jvF2gtA%3D%3D (Pubitemid 19086774)
83. C Querfeld N Mehta ST Rosen J Guitart A Rademaker P Gerami, et al. 2009 Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center Leuk Lymphoma 50 1969 1976 19860617 1:CAS:528:DC%2BD1MXhsFCiu7nP
84. MJ Dyer G Hale FG Hayhoe H Waldmann 1989 Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype Blood 73 1431 1439 2713487 1:STN:280:DyaL1M3ivFeltA%3D%3D (Pubitemid 19131883)
85. JR Salisbury NT Rapson JD Codd, et al. 1994 Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas J Clin Pathol 47 313 317 8027367 1:STN:280:DyaK2c3pvFymsw%3D%3D (Pubitemid 24171697)
86. L Riechmann M Clark H Waldmann, et al. 1998 Reshaping human antibodies for therapy Nature 332 323 327
87. PP Piccaluga C Agostinelli S Righi, et al. 2007 Expression of CD52 in peripheral T-cell Lymphoma Haematologica 92 566 567 17488672 (Pubitemid 350144307)
88. G Hale 2001 The CD52 antigen and development of the CAMPATH antibodies Cytotherapy 3 137 143 12171721 1:STN:280:DC%2BD38vhsF2ntg%3D%3D (Pubitemid 33039652)
89. MJ Dyer G Hale FG Hayhoe, et al. 1989 Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype Blood 73 1431 1439 2713487 1:STN:280:DyaL1M3ivFeltA%3D%3D (Pubitemid 19131883)
90. CE Dearden E Matutes B Cazin, et al. 2001 High remission rate in prolymphocytic leukemia with CAMPATH-1H Blood 98 1721 1726 11535503 1:CAS:528:DC%2BD3MXntFWgsb8%3D
91. A Gallamini F Zaja C Patti, et al. 2007 Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell Lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood 110 2316 2323 17581918 1:CAS:528:DC%2BD2sXhtFCnsbzL (Pubitemid 47523150)
92. MJ Keating B Cazin S Coutre, et al. 2002 Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed J Clin Oncol 20 205 213 11773171 1:CAS:528: DC%2BD38XnsFeqsw%3D%3D (Pubitemid 34032613)
93. G Enblad H Hagberg M Erlanson, et al. 2004 A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell Lymphoma Blood 103 2920 2924 15070664 1:CAS:528:DC%2BD2cXjsVahu78%3D (Pubitemid 38451660)
94. A Mijovic A Abdallah L Pearce, et al. 2008 Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimens Br J Haematol 142 444 452 18503585 1:CAS:528:DC%2BD1cXhtVWqu7rM (Pubitemid 351962186)
95. MG Bernengo P Quaglino A Comessatti, et al. 2007 Low-dose intermittent alemtuzumab in the treatment of Sezary syndrome: clinical and immunologic findings in 14 patients Haematologica 92 784 794 17550851 1:CAS:528: DC%2BD2sXhtFGqu73J (Pubitemid 350155304)
96. J Lundin H Hagberg R Repp, et al. 2003 Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fugoides/Sezary syndrome Blood 101 4267 4272 12543862 1:CAS:528: DC%2BD3sXktFKht7s%3D (Pubitemid 36857787)
97. P Weder M Anliker P Itin M Bargetzi 2004 Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab Dermatology 208 281 283 15118391 1:STN:280:DC%2BD2c3hvFOgtw%3D%3D (Pubitemid 38594554)
98. P Porcu RA Baiocchi J Lee TS Lin K Blum T Grady, et al. 2006 Phase I trial of subcutaneous (SQ) alemtuzumab (A) and CHOP in T-cell lymphoma: preliminary results [abstract] J Clin Oncol 24 (suppl 18S) 7594
99. C Querfeld TM Kuzel J Guitart, et al. 2005 Preliminary results of a phase II study of CC-5013 (Lenalidomide, Revlimid™) in patients with cutaneous T-cell lymphoma Blood 106 936a 937a
100. C Querfeld T Kuzel J Guitart, et al. 2009 Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma Hematology Meeting Reports 3 1 103 105 This publication highlighted the use of Lenalidomide as a potential treatment for CTCL.
101. FJ Kaye PA Bunn Jr SM Steinberg, et al. 1989 A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides N Engl J Med 321 1784 1790 2594037 1:STN:280:DyaK3c%2FotFOktQ%3D%3D (Pubitemid 20015571)
102. LM Krug KK Ng MG Kris, et al. 2000 Phase I and pharmacokinetic study of 10-propargyl- 10-deazaaminopterin, a new antifolate Clin Cancer Res 6 9 3493 3498 10999734 1:CAS:528:DC%2BD3cXntFCis70%3D
103. OA O'Connor 2006 Pralatrexate: an emerging new agent with activity in T-cell lymphomas Curr Opin Oncol 18 6 591 597 16988580 (Pubitemid 44427633)
104. OA O'Connor S Horwitz P Hamlin, et al. 2009 Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies J Clin Oncol 27 26 4357 4364 19652067 This article shared the results of a recent phase I/II trial with pralatrexate in CTCL patients.
105. PL Zinzani G Musuraca M Tani, et al. 2007 Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma J Clin Oncol 25 27 4293 4297 17709797 1:CAS:528:DC%2BD2sXhtFyis7jI (Pubitemid 47548570)
106. C Nabhan N Krett V Gandhi S Rosen 2001 Gemcitabine in hematologic malignancies Curr Opin Oncol 13 514 521 11673693 1:CAS:528:DC%2BD3MXos1OqsL4%3D (Pubitemid 33027905)
107. M Duvic R Talpur S Wen R Kurzrock CL David N Apisarnthanarax 2006 Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma Clin Lymphoma Myeloma 7 51 58 16879770 1:CAS:528:DC%2BD28XpsVakt7s%3D (Pubitemid 44322770)
108. PL Zinzani G Baliva M Magagnoli M Bendandi G Modugno F Gherlinzoni, et al. 2000 Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients J Clin Oncol 18 2603 2606 10893292 1:CAS:528:DC%2BD3cXltlKqt7s%3D (Pubitemid 30432527)
109. E Marchi L Alinari M Tani V Stefoni N Pimpinelli E Berti, et al. 2005 Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients Cancer 104 2437 2441 16216001 1:CAS:528:DC%2BD2MXhtlWgt7bK (Pubitemid 41691565)
110. DD Von Hoff S Dahlberg RJ Hartstock, et al. 1990 Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study J Natl Cancer Inst 82 16 1353 1355 (Pubitemid 20238491)
111. FM Foss DC Ihde DL Breneman, et al. 1992 Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome J Clin Oncol 10 12 1907 1913 1453206 1:STN:280:DyaK3s%2FosFeqsA%3D%3D (Pubitemid 23064202)
112. U Wollina R Dummer NH Brockmeyer, et al. 2003 Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma Cancer 98 5 993 1001 12942567 1:CAS:528:DC%2BD3sXns1Sjs7c%3D (Pubitemid 37022100)
113. C Querfeld ST Rosen J Guitart, et al. 2011 Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/SezarySyndrome: Correlation with O6-Methylguanine-DNA Methyltransferase andMismatch Repair Proteins Clin Cancer Res 17 17 5748 5754 21747120 1:CAS:528:DC%2BC3MXhtFSmtb%2FL This article was pivotal in suggesting the use of temozolomide for CTCL treatment.
114. L Liu S Markowitz SL Gerson 1996 Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea Cancer Res 56 5375 5379 8968088 1:CAS:528:DyaK28Xntl2mt70%3D (Pubitemid 27011367)
115. M Reni W Mason F Zaja, et al. 2004 Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial Eur J Cancer 40 1682 1688 15251157 1:CAS:528:DC%2BD2cXls1Wntr8%3D (Pubitemid 38902903)
116. MR Middleton JJ Grob N Aaronson, et al. 2000 Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma J Clin Oncol 18 158 166 10623706 1:CAS:528:DC%2BD3cXmtFSqsQ%3D%3D (Pubitemid 30036349)
117. ME Hegi AC Diserens S Godard, et al. 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 1871 1874 15041700 1:CAS:528:DC%2BD2cXisVGltbY%3D (Pubitemid 38375541)
118. G Akpek HK Koh S Bogen, et al. 1999 Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T cell lymphoma Cancer 86 1368 1376 10506727 1:CAS:528:DyaK1MXmsFOgsrk%3D (Pubitemid 29447025)
119. MT Fierro P Quaglino P Savoia A Verrone MG Bernengo 1998 Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP Leuk Lymphoma 31 5-6 583 588 9922049 1:CAS:528:DC%2BD3cXlsV2kurk%3D (Pubitemid 29050600)
120. A Mebazaa A Dupuy M Rybojad F Mouly I Moulonguet MD Vignon-Pennamen J Rivet A Janin C Lebbé L Dubertret P Morel H Bachelez P Brice 2005 ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients Hematol J 5 7 553 558 15692599 (Pubitemid 40309619)
121. RF Duarte N Schmitz O Servitje, et al. 2008 Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma Bone Marrow Transplant 41 597 604 18176611 1:STN:280:DC%2BD1c3js1KlsA%3D%3D (Pubitemid 351523997)
122. PA Wu YH Kim PW Lavori, et al. 2009 A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome Biol Blood Marrow Transplant 15 982 990 19589488
123. RF Duarte C Canals F Onida, et al. 2010 Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J Clin Oncol 28 29 4492 4499 20697072 This article reports results from the first large multicenter analysis of alloHCT for MF/SS patients.
124. E Carrié A Buzyn S Fraitag, et al. 2007 Transformed juvenile-onset mycosis fungoides: Treatment by bone marrow transplantation with graft-versus-lymphoma effect Ann Dermatol Venereol 134 471 476 17507848 (Pubitemid 46797781)
125. IH Gabriel E Olavarria RR Jones, et al. 2007 Graft versus lymphoma effect after early relapse following reduced intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides Bone Marrow Transplant 40 401 403 17589536 1:STN:280:DC%2BD2svkvVajsA%3D%3D (Pubitemid 47202430)
126. D Soligo A Ibatici E Berti, et al. 2003 Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen Bone Marrow Transplant 31 663 666 12692606 1:STN:280: DC%2BD3s7ntlekug%3D%3D (Pubitemid 36553476)
127. RK Burt J Guitart A Traynor, et al. 2000 Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: Evidence of a graft-versus-tumor effect Bone Marrow Transplant 25 111 113 10654025
128. A Molina J Zain DA Arber, et al. 2005 Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sézary syndrome and mycosis fungoides J Clin Oncol 23 6163 6171 16135483
129. RF Duarte N Schmitz O Servitje, et al. 2008 Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma Bone Marrow Transplant 41 597 604 18176611 1:STN:280:DC%2BD1c3js1KlsA%3D%3D (Pubitemid 351523997)
130. M Duvic M Donato B Dabaja, et al. 2010 Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome J Clin Oncol 28 14 2365 2372 20351328
131. BioCryst Pharmaceuticals. Forodesine in the treatment of cutaneous T-cell lymphoma [ClinicalTrials.gov identifier NCT00501735]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www. clinicaltrials.gov
132. DA Rider CEG Havenith R de Ridder J Schuurman C Favre JC Cooper, et al. 2007 A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity Cancer Res 67 9945 9953 17942927 1:CAS:528:DC%2BD2sXhtFOnsbnJ (Pubitemid 47621244)
133. JM Reichert 2011 Antibody-based therapeutics to watch in 2011 MAbs 3 76 99 21051951 This article informed about the newest antibody therapies which are applicable to CTCL treatment.